Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action

ALTEX. 2014;31(4):500-19. doi: 10.14573/altex.1401281. Epub 2014 Jan 28.

Abstract

A workshop sponsored by the Human Toxicology Project Consortium (HTPC), "Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action" brought together experts from a wide range of perspectives to inform the process of pathway development and to advance two prototype pathways initially developed by the European Commission Joint Research Center (JRC): liver-specific fibrosis and steatosis. The first half of the workshop focused on the theory and practice of pathway development; the second on liver disease and the two prototype pathways. Participants agreed pathway development is extremely useful for organizing information and found that focusing the theoretical discussion on a specific AOP is extremely helpful. In addition, it is important to include several perspectives during pathway development, including information specialists, pathologists, human health and environmental risk assessors, and chemical and product manufacturers, to ensure the biology is well captured and end use is considered.

MeSH terms

  • Animal Testing Alternatives*
  • Animals
  • Chemical and Drug Induced Liver Injury / pathology*
  • Drug-Related Side Effects and Adverse Reactions*
  • Toxicity Tests / methods*